Smallpox

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December

Retrieved on: 
Tuesday, November 28, 2023
Long COVID, Hydrogen chloride, Upsher-Smith Laboratories, Long, Failure, Infection, Breakthrough therapy, NIAID, Binge eating disorder, Government, Psychiatry, Research, Sumatriptan, FDA, Pain, Prader–Willi syndrome, Cancer, CD40L, Orphan drug, Social anxiety disorder, Risk, Disease, COVID-19, Fibromyalgia, Obesity, CNS, Smallpox, Virtual, Neurology, NIH, Central nervous system, Therapy, Security (finance), Annual report, Autoimmunity, Pharmaceutical industry

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Key Points: 
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
  • Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Mpox (Monkeypox) Vaccine Triggers Equally Strong Immune Response in Smaller Than Usual Doses and in People With or Without HIV

Retrieved on: 
Thursday, December 14, 2023
World Health Organization, NYU Langone Health, Mental Hygiene, Research, National Institutes of Health, New Yorker, Coinfection, Risk, Congo, Vaccination, Infection, Death, FDA, Division, Mpox, CD4, Master of Science, NYU, HIV, CDC, Antibody, Doctor of Philosophy, Skin, Jeff Kottkamp, Injection, Face, Immunoglobulin G, Smallpox, Democratic republic, Vaccine, Pharmaceutical industry, MD

Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.

Key Points: 
  • Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.
  • The smaller doses, about one-fifth of the usual full dose and spread out by as long as three months, were designed to stretch the short supply of vaccine available after an outbreak in May 2022.
  • The IgG antibodies were detected in some cases more than six months after a second and final dose of the vaccine.
  • The mpox vaccine is now routinely recommended by the Centers for Disease Control and Prevention (CDC) for people at risk.

Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Retrieved on: 
Thursday, November 2, 2023
Monkeypox virus, FDA, National Institute of Allergy and Infectious Diseases, HHS, Food, Therapy, Vaccine, SARS-CoV-2, NIAID, Face, Mpox, Project, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, Tonix Pharmaceuticals, Clinical trial, COVID-19, Smallpox, Nextgen, Animal, RPV, NIH, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Infection, Tuberculosis, Bangladesh Technical Education Board

CHATHAM, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.

Key Points: 
  • Tonix is developing a novel vaccine platform initially targeting COVID-19, smallpox and mpox (monkeypox).
  • The intent is to provide durable protection against severe disease and prevent forward transmission, primarily by eliciting a T-cell immune response.
  • “TNX-1800 will be the first vaccine candidate using our live virus recombinant pox virus (RPV) platform technology to enter clinical trials.
  • NIAID will be conducting clinical trials to evaluate several early-stage vaccine candidates.

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Retrieved on: 
Monday, October 30, 2023
Massachusetts General Hospital, Long, Faculty, Orphan drug, Research, American College, Prader–Willi syndrome, Gustav Neuring, Therapy, Obesity, Hydrogen chloride, Binge eating disorder, SL, COVID-19, Smallpox, Pain, Psychiatry, Sumatriptan, MDD, DSM-IV codes, Cell Transplantation, Social anxiety disorder, Upsher-Smith Laboratories, GE, Fibromyalgia, Transplant, MGH, Cancer, Central nervous system, Ischemia, Long COVID, Security (finance), Infection, CD40L, Congress, Survival, Disease, Breakthrough therapy, Animal, Planning, FDA, Autoimmunity, Government, CNS, Neurology, Risk, Science, ACS, PPAR, Annual report, Gujarat University of Transplantation Sciences, Failure, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

CHATHAM, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently at the American College of Surgeons (ACS) Clinical Congress 2023, and The International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA), and the Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in October 2023. The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection. Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com.

Key Points: 
  • The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection.
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com .
  • include data demonstrating the use of TNX-1500 as maintenance therapy after xeno heart transplant in non-human primates.
  • In both studies, genetically engineered (GE) pigs in baboon transplants were treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen including TNX-1500.

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

Retrieved on: 
Monday, October 23, 2023
European Commission, TPOXX, SIGA Technologies, Health Emergency Preparedness and Response Authority, Meridian Medical Technologies, Civil service commission, European Free Trade Association, EFTA, European, Smallpox, Vaccine, EU

Based on commitments from EU member countries, it is currently anticipated that $18 million in approximate value of oral TPOXX will be initially ordered by EU countries under this mechanism within the next 60 days.

Key Points: 
  • Based on commitments from EU member countries, it is currently anticipated that $18 million in approximate value of oral TPOXX will be initially ordered by EU countries under this mechanism within the next 60 days.
  • Orders through the joint procurement mechanism will result in country-level procurement of oral TPOXX.
  • Separately, as announced in September of 2022, the European Commission procured oral TPOXX through the funding of a direct purchase.
  • “With the creation of a joint procurement mechanism, there are now multiple paths in Europe for efficient procurement of oral TPOXX,” said Phil Gomez, CEO of SIGA.

Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe

Retrieved on: 
Thursday, October 19, 2023
Survival, Immunodeficiency, Vaccine, Weight loss, Orthopoxvirus, Medicine, Mpox, Virus, Mouse, Science, Smallpox, Thermoregulation, Infection, Nineteenth Air Force, Tonix Pharmaceuticals

CHATHAM, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, presented data on its horsepox-based live virus vaccine platform in an oral presentation at the World Vaccine Congress Europe being held in Barcelona, Spain, October 16-19, 2023. A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • CHATHAM, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, presented data on its horsepox-based live virus vaccine platform in an oral presentation at the World Vaccine Congress Europe being held in Barcelona, Spain, October 16-19, 2023.
  • A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com .
  • Our lead vaccine candidate, TNX-8011, is in development to protect against Mpox (monkeypox) and smallpox.
  • Together, these data suggest that TNX-801 potentially should be a safer vaccine in immunocompromised populations than many VACV-based vaccines.”

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA

Retrieved on: 
Monday, October 23, 2023
Other Defense, Infectious Diseases, Contracts, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Defense, European Economic Area, Vaccinia, Medication, SIGA Technologies, Cowpox, Health Emergency Preparedness and Response Authority, Mpox, Meridian Medical Technologies, European Medicines Agency, JPA, MHRA, European, HERA, Smallpox, Tecovirimat, EMA, Joint, Gross metropolitan product, Medicines and Healthcare products Regulatory Agency, Health technology, Patient, Vaccine, Nursing, Meridian, EEA, EU

Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).
  • As part of a promotional licensing agreement, Meridian is a global commercialization partner for SIGA Technologies, Inc. (NASDAQ: SIGA), which is the marketing authorization holder and manufacturer of Tecovirimat SIGA.
  • Under the JPA, 13 participating countries from the European Economic Area (EEA) (Contracting Parties) can now efficiently purchase Tecovirimat SIGA, which has been approved by the European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
  • This agreement will result in country-level procurement of oral Tecovirimat SIGA and serve as a template for future procurement opportunities.

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

Retrieved on: 
Thursday, October 12, 2023
SL, Autoimmunity, Government, Headache, DSM-IV codes, CD40L, Research, Risk, Infection, COVID-19, Binge eating disorder, Smallpox, Central nervous system, Upsher-Smith Laboratories, Fibromyalgia, Hydrogen chloride, Annual report, Prader–Willi syndrome, PPAR, Pain, Obesity, Sumatriptan, Breakthrough therapy, Neurology, Cancer, FDA, Long, IR, Migraine, CNS, MDD, Security (finance), Disease, Therapy, Failure, ThinkEquity, Mandarin Oriental Hotel Group, Long COVID, Gustav Neuring, Social anxiety disorder, Orphan drug, Psychiatry, Conference, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.

Key Points: 
  • CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe

Retrieved on: 
Wednesday, October 11, 2023
SL, Autoimmunity, Government, Medicine, Headache, DSM-IV codes, CD40L, Research, Risk, Infection, COVID-19, Binge eating disorder, Smallpox, Central nervous system, Upsher-Smith Laboratories, Fibromyalgia, Hydrogen chloride, Annual report, Prader–Willi syndrome, PPAR, Pain, Obesity, Sumatriptan, Breakthrough therapy, Neurology, Cancer, CEST, FDA, Long, Migraine, CNS, MDD, Security (finance), Disease, Congress, Therapy, Failure, Long COVID, Gustav Neuring, Science, Social anxiety disorder, Orphan drug, Psychiatry, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Key Points: 
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the World Vaccine Congress website here .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.

'We could eradicate malaria by 2040' says expert after revolutionary vaccine is approved by WHO

Retrieved on: 
Tuesday, October 3, 2023
People, Well, Vaccine, Infection, University of Oxford, Serum Institute of India, International, Human, University, Parasitism, Vaccination, COVID-19, Jenner Institute, Immunity, Smallpox, Antibody, Blood, Biological life cycle, Coma, World Health Organization, Liver, World, Gene, Skin, Pharmaceutical industry, Oyster farming, UNICEF, Malaria

Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.

Key Points: 
  • Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.
  • The Conversation Weekly spoke to chief investigator Adrian Hill, who is also director of the Jenner Institute at the University of Oxford, about this revolutionary vaccine.

Why is the R21/Matrix vaccine a game-changer?

    • The best vaccine prior to this was about 50% over a year, and lower than that over three years.
    • The big difference is how you can manufacture it at a scale that is really needed to protect most of the children who need a malaria vaccine in Africa.
    • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.

Why has developing a malaria vaccine been so difficult?

    • Malaria is not a virus, it’s not a bacterium.
    • This is one of the reasons that malaria is super complex.
    • If you can get a really good vaccine for one of those, you will break the cycle of transmission.
    • It’s a silent infection until it gets into the blood and starts multiplying inside your red blood cells.
    • So the sporozoite is a natural target to try and kill the parasite before it multiplies very quickly.

Tell us about past attempts to develop a malaria vaccine

    • In about 1943, there was a trial of the whole malaria parasite vaccine candidate in New York with zero efficacy.
    • And then within 10 years we had 5,000 candidates because everyone hoped that the gene they had sequenced might be a malaria vaccine.

Why aren’t vaccines for whole parasites effective against malaria?

    • It’s the same reason that just getting infected once by malaria doesn’t give you protection against the next infection.
    • In the areas of malaria where we test our vaccines in Africa, some children get up to eight episodes in three or four months.
    • They get quite unwell with the first and three weeks later they’re having a second bout and so on.

Will we ever eradicate malaria entirely?

    • Malaria is very high on the list of diseases we want to eradicate.
    • I don’t think it’s going to happen in five years or 10 years, but it should happen in something like 15 years.